↓ Skip to main content

Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

blogs
1 blog
twitter
2 X users
patent
8 patents
googleplus
1 Google+ user

Citations

dimensions_citation
58 Dimensions

Readers on

mendeley
107 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors
Published in
Journal for Immunotherapy of Cancer, July 2013
DOI 10.1186/2051-1426-1-11
Pubmed ID
Authors

Willem W Overwijk, Ena Wang, Francesco M Marincola, Hans-Georg Rammensee, Nicholas P Restifo, for the Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy

Abstract

T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode unique peptides (m-peptides) that can be targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 3%
Korea, Republic of 1 <1%
Brazil 1 <1%
Unknown 102 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 21%
Researcher 20 19%
Student > Master 12 11%
Other 11 10%
Student > Bachelor 7 7%
Other 18 17%
Unknown 17 16%
Readers by discipline Count As %
Agricultural and Biological Sciences 32 30%
Medicine and Dentistry 23 21%
Biochemistry, Genetics and Molecular Biology 18 17%
Immunology and Microbiology 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 4 4%
Unknown 22 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2023.
All research outputs
#1,929,404
of 25,373,627 outputs
Outputs from Journal for Immunotherapy of Cancer
#509
of 3,421 outputs
Outputs of similar age
#16,243
of 209,985 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 7 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,985 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them